生殖器疱疹合并感染的临床研究

目的:分析并探讨生殖器疱疹合并感染的临床特点,从而为临床诊断提供依据。方法:选取2010年1月至2016年1月期间在我院就诊的性病门诊患者574例。采用回顾性分析的方法,总结患者临床资料,分析临床特征。结果:574例患者中,生殖器疱疹372例,占64.81%,硬下疳占17.42%,淋菌性包皮龟头炎占1.74%,念珠菌性包皮龟头炎占3.66%,白塞病占1.22%,其他类型占11.15%。372例生殖器疱疹患者平均年龄为(36.35±6.34)岁,男性患者占78.23%,女性占21.77%。初次发病占30.11%,复发占69.89%。合并其他感染87例,占23.39%,其中以合并尖锐湿疣为主,占8.60%。HSV-1感染者24例(6.54%),HSV-2感染者348例(23.39%)。所有合并感染者均为HSV-2感染者。结论:生殖器疱疹是临床常见性病之一,容易合并其他性传播疾病,HSV-2型为易感其他疾病类型,临床上要早期诊断。     

生殖器疱疹患者530例HSV抗体型别检测分析

目的了解生殖器疱疹患者HSV-1和HSV-2的感染情况,并分析生殖器疱疹的流行特点。方法采用酶联免疫吸附试验(ELISA)法对性病门诊530例临床诊断为生殖器疱疹的患者进行了HSV血清抗体检测。结果 530例中男311例(58.68%),女219例(41.32%)。HSV-1IgM抗体阳性60例(11.32%),HSV-1IgG抗体阳性471例(88.87%),HSV-2IgM抗体阳性213例(40.19%),HSV-2IgG抗体阳性349例(65.85%)。年龄以31～40岁最多,为210例,其次为21～30岁194例。职业中最多的是自由职业和民工。初发者304例(57.36%),复发者226例(42.64%),其中频繁发作(≥6次/年)85例(16.04%)。结论长春地区生殖器疱疹患者以HSV-2感染为主。女性近期感染多于男性。以21～40岁性活跃人群为高发年龄组。     

女性原发性生殖器疱疹中HSV-Ⅱ的检测及意义

目的探讨单纯疱疹病毒Ⅱ型(HSV-Ⅱ)与女性原发性生殖器疱疹(GH)的相关性及意义。方法应用酶联免疫吸附法(ELISA)分别检测患者血清中HSV-Ⅱ抗体以及分泌物中的HSV-Ⅱ抗原。结果HSV-Ⅱ中IgG均阴性的138例女性生殖器疱疹患者中HSV-Ⅱ抗原阳性78例(56.52%);HSV-Ⅱ中IgM抗体阳性130例(94.20%),抗体阳性率明显高于抗原阳性率(P<0.01)。典型病例组抗原阳性65例(87.84%),IgM抗体阳性66例(89.19%);不典型病例组抗原阳性13例(20.31%),IgM抗体阳性64例(100.00%)。结论对于皮损时间短,症状典型者可检测HSV-Ⅱ抗原;皮损时间长,或反复者可检测HSV-Ⅱ抗体,可以有效提高HSV感染的临床诊断率。     

单纯疱疹病毒2型血清IgG及IgM抗体的酶免疫检测

单纯疱疹病毒2型(HSV-2)主要感染腰以下部位(如生殖器、肛门等),多通过性交而传染、在我国,生殖器疱疹已不少见^[1],为了解该病的发病情况,人群中HSV-2感染状况及机体对其免疫反应,我们采用德国Virotech公司生产的HSV-2IgG及IgM抗体酶免疫试剂检测生殖器疱疹病人及正常人,现将结果报告如下。一、检测对象病例选择:60例均为我院性病门诊病人,临床诊断为生殖器疱疹。男54例,女6例;年龄20～52岁(平均28岁);病期2天至3年不等。大多数病人有非婚性接触史。原发型15例(25%),复发型45例(75%)。     

评价在辅助生育中检测单纯疱疹病毒2抗体对诊断生殖器疱疹的意义

【摘要】 目的 在分析生殖器疱疹患者单纯疱疹病毒（HSV）流行株的基础上,探讨HSV-2 IgM抗体、型特异HSV-2 IgG抗体的敏感性、特异性、阴性预测值和阳性预测值,评价辅助生育中二种抗体检测在诊断生殖器疱疹上的意义。 方法 对2009—2011年中山大学附属第一医院皮肤科193例生殖器疱疹患者临床分离病毒株培养并鉴定分型,了解主要的流行病毒型。生殖中心术前筛查HSV-2 IgM和（或）IgG阳性、疑诊生殖器疱疹的女性,丈夫同时抽血检查,共57对为临床观察组;选取HSV培养阳性生殖器疱疹患者68例作为阳性对照组;8 ~ 10岁儿童120例为阴性对照组。血清标本采用酶联免疫吸附法（ELISA）检测HSV-1 IgM和HSV-2 IgM抗体及型特异HSV-1 IgG、HSV-2 IgG抗体,对结果进行比对分析。 结果 阳性对照组68例中,HSV-1 IgM 14例（20.59%）、HSV-2 IgM 9例（13.24%）、HSV-1 IgG 61例（89.71%）、HSV-2 IgG 62例（91.18%）阳性;阴性对照组120例,分别为26例（21.70%）、16例（13.30%）、49例（40.80%）和0例阳性;两组HSV-1 IgM及HSV-2 IgM阳性率差异均无统计学意义（P > 0.05）,但HSV-1 IgG及HSV-2 IgG阳性率差异均有统计学意义（P < 0.01）。临床观察组57例女性中,HSV-1 IgM 46例（80.70%）、HSV-2 IgM 52例（91.23%）、HSV-1 IgG 48例（84.21%）、HSV-2 IgG 8例（14.04%）阳性;男性（配偶）分别为11例（19.30%）、5例（8.77%）、50例（87.71%）和7例（12.28%）阳性;两性的HSV-1 IgM及HSV-2 IgM阳性率差异均有统计学意义（P < 0.01）,而HSV-1 IgG及HSV-2 IgG阳性率差异均无统计学意义（P > 0.05）。HSV-2 IgM诊断生殖器疱疹的敏感性为13.24%,特异性为86.67%,阳性预测值36.00%,阴性预测值63.80%;HSV-2 IgG诊断生殖器疱疹的敏感性91.18%,特异性100.00%,阳性预测值100.00%,阴性预测值95.24%。 结论 该地区生殖器疱疹主要流行病毒型为HSV-2,仅5.18%是HSV-1。HSV-2 IgM诊断生殖器疱疹的敏感性、阳性预测值以及特异性、阴性预测值均低于HSV-2 IgG;辅助生育中型特异性HSV-2 IgG检测在诊断生殖器疱疹上的意义大于HSV-2 IgM。 【关键词】 疱疹,生殖器; 单纯疱疹病毒属; 免疫球蛋白G; 免疫球蛋白M     

80例首诊生殖器疱疹及其配偶生殖器疱疹发展情况分析

目的:了解生殖器疱疹在夫妻间的传播情况.方法:对80例首诊为生殖器疱疹的患者及其配偶的临床资料进行分析.结果:夫妻同患生殖器疱疹50对,占62.5%,其中男性首诊者32例,主要为复发性生殖器疱疹,女性首诊者18例,主要为亚临床感染及复发性生殖器疱疹.50对患者中,在夫妻一方首诊为生殖器疱疹后,有38例的配偶同时被诊断为生殖器疱疹,其余12例在追踪3个月至1年后才被确诊.配偶被追踪诊断的生殖器疱疹中女性主要为亚临床感染,占50%(16/32),男性主要为复发性生殖器疱疹,占55.5%(10/18).结论:夫妻同患生殖器疱疹比例较高,亚临床感染发生率较高,皮损呈多形性,早期诊断较难.     

177例可疑生殖器疱疹患者HSV-ⅡIgM/IgG抗体检测结果分析

目的:探讨Ⅱ型单纯疱疹病毒抗体(HSV-ⅡIgM/IgG)与生殖器疱疹的相关性,辅助临床诊断。方法:应用酶联免疫吸附试验(ELISA)检测血清中HSV-ⅡIgM/IgG抗体,并用PCR荧光定量法检测分泌物的HSV-Ⅱ抗原(HSV-Ⅱ-DNA)进行对比。结果:177例可疑生殖器疱疹患者检出HSV-Ⅱ抗原131例,阳性率为74.0%;检出HSV-ⅡIgM和(或)IgG共144例,阳性率为81.4%,两者没有显著性差异(2=2.96,P>0.05)。其中19例为结痂型的患者中,HSV-Ⅱ抗原阳性4例,阳性率21.1%;而HSV-Ⅱ抗体阳性14例,阳性率为73.7%。结论:同时检测血清中HSV-ⅡIgG和HSV-ⅡIgM作为生殖器疱疹筛查试验,有利于症状不典型的HSV-Ⅱ感染者的检出,提高诊断率。     

性病门诊836例患者单纯疱疹Ⅰ,Ⅱ型检测结果分析

目的探讨性病专科门诊患者中HSV-Ⅰ,Ⅱ型病毒的感染情况及在典型和非典型生殖器疱疹(GH)患者中的分布。方法采用荧光定量聚合酶链反应技术(FQ-PCR)对836例性病专科门诊患者进行HSV-Ⅰ,Ⅱ型DNA的检测。结果836例患者中,HSV-Ⅰ型感染38例(4.54%),男性阳性率5.20%,女性为3.36%,二者差异无显著性;HSV-Ⅱ型感染380例(45.45%),男性阳性率39.96%,女性为55.37%,二者差异有显著性(P<0.05)。具有典型GH或高度可疑GH症状者369例,HSV感染者218例;无明显GH症状者467例,HSV感染者198例,二者差异有显著性(P<0.05)。结论HSV在本地区具有较高感染率,以HSV-Ⅱ型为主。在非典型GH患者中,HSV的检出率较高,须引起临床注意。     

对ELISA检测生殖器疱疹患者HSV及其临床应用的评价

目的评价酶联免疫吸附试验(ELISA)检测生殖器疱疹病毒的临床应用价值。方法采用ELISA和分型聚合酶链反应(分型PCR)检测生殖器标本中的单纯疱疹病毒(HSV),两种试验结果不符合者采用不分型PCR检测。结果164例受检者中,ELISA法HSV阳性96例(58.5%),其中具典型皮损者阳性84例(80.8%,84/104),非典型皮损阳性12例(20.0%,12/60);分型PCRHSV阳性98例(59.8%),其中典型皮损者HSV阳性86例(82.7%,86/104),非典型皮损者阳性12例(20.0%,12/60)。HSV1感染者占生殖器疱疹的5.1%,HSV2感染占88.7%,HSV1和HSV2混合感染者占6.1%。ELISA的敏感性和特异性分别为96.7%和94.0%。结论ELISA检测HSV感染,其敏感性高、特异性强,方便、快速,尤其适合大批量样本的检测。     

生殖器疱疹临床诊疗指南(2009)

一、定义 生殖器疱疹是由单纯疱疹病毒(herpes simplex virus,HSV)感染泌尿生殖器及肛门部位皮肤黏膜而引起的性传播疾病.HSV可分为1型(HSV-1)和2型(HSV-2),生殖器疱疹主要由HSV-2引起,也可由HSV-1或两型混合感染所致.     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.